Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer
GSK announced submission of MAA to EMEA for pazopanib, oral therapy for metastatic renal cell carcinoma (RCC).
-
NICE refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib)
NICE issued appraisal against NHS funding for Tyverb, treatment for breast cancer (ErbB2-positive).1.
-
GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)
GSK announced start of the Phase III clinical trial programme of GLP-1 agonist Syncria in men and women with type 2 diabetes.
-
GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide license agreement for IDX899, a novel NNRTI for the treatment of HIV
GSK & Idenix announced agreement granting GSK exclusive worldwide rights to IDX899, a NNRTI in Phase II, treatment of HIV/AIDS.
-
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer
GSK & Genmab announced submission of MAA to EMEA for Arzerra, treatment of CLL, it targets a binding site on the CD20 molecule of B-cells.
-
Results announcement for the fourth quarter 2008
See the quarterly results page for more information.
-
GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma
Data increase confidence in the Horizon development programme
-
GlaxoSmithKline plc, announces board changes
GSK announces, Mr. James Murdoch has been appointed as a Non-Executive Director and will join the Board of the Company from 20/05/09.
-
GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer
GSK & GEN announced submission of BLA to the FD) for Arzerra to treat patients whose CLL is resistant (refractory) to previous therapies.
-
Deirdre Connelly to join GSK as President, North American Pharmaceuticals
GSK announced, Deirdre Connelly will join the company as President, North American Pharmaceuticals, effective Monday 9 February 2009.
-
GSK announces charges for legal matters
GSK today announced that it will record a legal charge in the fourth quarter of 2008 of $400 million elating to an ongoing investigation.
-
The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®
The UK is now one of the leading countries in stockpiling antivirals for treating infected individuals in event of an influenza pandemic
-
GSK to drive growth in emerging markets with acquisition of UCB products
GSK signed an agreement with UCB S.A to acquire its portfolio across Africa, the Middle East, Asia Pacific and Latin America, for €515 m.
-
GSK’s paediatric pneumococcal candidate vaccine Synflorix™ receives positive opinion in Europe
Serotypes included in the vaccine are responsible for up to 90% of invasive pneumoccal disease in young children in Europe. 1,2,3
-
GlaxoSmithKline receives European Commission approval to market alli® (orlistat 60mg)
EC opens access to a treatment for people who are overweight and obese. GSK has received a non-prescription licence for alli (orlistat 60mg
-
GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome
GSK & XenoPort have resubmitted NDA to the FDA for approval of Solzira Extended Release Tablets, treatment of moderate-to-severe primary RLS
